Latest Filings

Issuer Activity

Insider Overview :: Allegiance Equity Corporation (V:ANQ) [?]
Business Focus: Generic Pharmaceuticals
Recent Price for ANQ
CAD 0.085 0.00 (0.00%)
TSXV Delayed 15 minutes
Jun 18 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 0.260 0.0 N/A 0.71
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 0.050 0.0% 5,000  
Log in or sign up for a free account to add this stock to your watch list.
Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for ANQ within the last 6 months [?]
Amended Filing
As of 11:59pm ET June 18th, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Jun 18/13 Jun 18/13 Bookalam, Philip Charles Direct Ownership Options 52 - Expiration of options -166,000 $0.300
Mar 11/13 Mar 8/13 Bloovol, Marilyn Indirect Ownership Common Shares 11 - Acquisition carried out privately 233,333 $0.150
Mar 11/13 Mar 8/13 Solomon, David Samuel Indirect Ownership Common Shares 11 - Acquisition carried out privately 233,333 $0.150
Mar 8/13 Mar 8/13 Warburton, George Anthony Indirect Ownership Common Shares 11 - Acquisition carried out privately 510,567 $0.150
Mar 8/13 Mar 8/13 Goldberg, Melvin Direct Ownership Common Shares 11 - Acquisition carried out privately 80,000 $0.150
Feb 6/13 Feb 4/13 Goldberg, Melvin Direct Ownership Common Shares 10 - Disposition in the public market -75,000 $0.200
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for ANQ within the last 6 months [?]
Amended Filing
As of 11:59pm ET June 18th, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Jun 18/13 Jun 18/13 Bookalam, Philip Charles Direct Ownership Options 52 - Expiration of options -166,000 $0.300
Mar 11/13 Mar 8/13 Bloovol, Marilyn Indirect Ownership Common Shares 11 - Acquisition carried out privately 233,333 $0.150
Mar 11/13 Mar 8/13 Solomon, David Samuel Indirect Ownership Common Shares 11 - Acquisition carried out privately 233,333 $0.150
Mar 8/13 Mar 8/13 Warburton, George Anthony Indirect Ownership Common Shares 11 - Acquisition carried out privately 510,567 $0.150
Mar 8/13 Mar 8/13 Goldberg, Melvin Direct Ownership Common Shares 11 - Acquisition carried out privately 80,000 $0.150
Feb 6/13 Feb 4/13 Goldberg, Melvin Direct Ownership Common Shares 10 - Disposition in the public market -75,000 $0.200
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for ANQ on June 18, 2013 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
Key People
David S. Solomon
President, Director 		Marilyn H. Bloovol
Secretary, Director 		 
Company Contact
Address: 3, 1845 Sandstone Manor
PICKERING ON M5P 2R6
Tel: N/A
Website: www.allegianceequity.com
IR: www.allegianceequity.com/#!investors
Business Overview
Allegiance Equity Corporation (Allegiance) is a Canada-based Company engaged in providing financial and business advises to emerging corporations primarily in the pharmaceutical, medical and biotechnology industries. The Company develops standardized mass market products for treatment of common diseases where present pharmaceutical treatments and over the counter (OTC) products are inadequate. The Company's products include: CinGx and Relieva. CinGx offers a new option in the fight against Diabetes and for individuals suffering from Alzheimer's and Dementia. Relieva is made with Psorberine an anti-inflammatory, antibacterial product for the treatment of psoriasis and atopic dermatitis. Relieva provides immediate relief for itching, irritation and inflammation associated with almost all problem skin conditions and, importantly, has ZERO toxicity and irritation. The subsidiary of the Company is Prime Pharmaceutical Corporation (Prime).
Competitors with Recent Insider Filings
Merus Labs Intl (T:MSL)
 
Allegiance Equity Corporation Insider Report Only $20.00